The unique approach in WOUNDCOM is the use of molecules derived from human collagen VI and their combination with a biomembrane. Our product acts locally in a wound bed mimicking natural collagen VI upregulation in the healing process and avoids systemic exposure, paving the way for a favorable safety profile. Our compounds proved more effective in combating bacterial wound infections and with no cytotoxic side effects.
This unique solution creates a new category of wound care products and addresses a new market segment of interactive biomembranes on the global market.
Our solution can be used in acute as well as in chronic wounds. Faster and more efficient treatment of acute and chronic wounds implies several benefits for patients and medical professionals and will increase demand for WOUNDCOM in hospitals and clinics.
Moreover, as our invention has defined antibacterial effects against all bacteria tested so far, including multidrug resistant bacteria, it will combat multidrug resistance (listed by the WHO as one of the biggest threats to global health).
The development of the WOUNDCOM product will certainly contribute to reach United Nation’s third sustainable development goal – to ensure healthy lives and promote well-being for all at all ages. By bringing to the market an effective and sustainable product that improves wound treatment, wound management will take an important step towards eliminating the risk of acquiring bacterial infections, combattin multidrug resistance, reducing antibiotics use, thus increasing effectiveness of wound healing. This is a clearly stated issue, proving that WOUNDCOM contributes to reach UN’s goals.
Dr Suado Abdillahi, inventor and cofounder of Colzyx AB
ColZyx is a great example of basic reseach findings that can be applicable in product development. WOUNDCOM and other product developed through Colzyx' platform will have a great impact on the well being of millions of people all around the globe.
As a PhD student in Matthias Mörgelins laboratory at Lund University Suado Abdillahi publish her initial finding that Collagen VI encodes antimicrobial avtivity. This work acts as a starting point for what would become the foundation of the Colzyx technology.
Eskil Söderlind had met with Matthias already in 2010. When making the Collagen VI discoveries Mattias decided to contact Eskil and present his ideas and see if there was an opportunity of a product development. Eskil presented the idea to his business partner Karin Bryder and they decided to evaluate the possibilities further.
Colzyx AB was founded by the two inventors Soade Abdillahi and Matthias Mörgelin together with Karin Bryder and Eskil Söderlind acting through Avena Partners AB.
A patent application was filed.
A first seed investment was made by the CBC investment group.
The WOUNDCOM project was awarded “Seal of Excellence” from the European Commission